Key Highlights
- BillionToOne shares are trading up 3.50% today to $147.23, pushing toward their 52-week high of $147.69.
- The company is scheduled to release second-quarter 2026 results after today's market close, with a conference call at 4:30 p.m. Eastern time.
- Analysts expect EPS of approximately $0.07 and revenue of roughly $109 million to $117 million for the quarter.
- The company beat expectations significantly last quarter, posting EPS of $0.34 versus a $0.01 estimate and revenue of $108.4 million against a $95.8 million consensus.
- Recent 13F filings show funds including Perceptive Advisors and Ohio's Public Employees Retirement System building or adding to positions.
What's Driving Shares Today
BillionToOne (NASDAQ:BLLN) is a Menlo Park, California-based precision diagnostics company founded in 2016 by Dr. Oguzhan Atay and Dr. David Tsao, dedicated to making molecular diagnostics more powerful, efficient, and accessible. Its patented Quantitative Counting Templates platform is a proprietary molecular counting technology capable of detecting and quantifying DNA molecules at the single-molecule level, enabling highly sensitive disease detection across the company's prenatal screening and oncology diagnostics segments.
Shares are trading modestly higher today ahead of tonight's second-quarter earnings report, due after market close with a conference call scheduled for 4:30 p.m. Eastern time. Continued institutional accumulation and bullish sentiment appear to be supporting the molecular diagnostics name, as investors position for the print.
Strong Track Record Heading Into the Print
The company's UNITY Complete non-invasive prenatal test has captured roughly 15% of the U.S. market, while its Northstar Select and Northstar Response liquid biopsy tests serve the oncology side of the business for tumor mutation profiling and treatment monitoring. Analysts expect second-quarter EPS of approximately $0.07 on revenue of roughly $109 million to $117 million, following a first-quarter beat in which the company posted EPS of $0.34 versus a $0.01 estimate and revenue of $108.4 million against a $95.8 million consensus, representing 83.8% year-over-year growth.
Recent 13F filings show funds including Perceptive Advisors and Ohio's Public Employees Retirement System building or adding to positions following that strong first-quarter beat, even as insiders including CTO David Tsao and Chief Product Officer Shan Kakarala have continued selling shares from recent Form 4 filings.
Broader Sector Backdrop
The move also comes amid a broader healthcare sector uptick, with strong ISM manufacturing data and a wave of positive second-quarter diagnostics-sector earnings from peers including Revvity and IDEXX Laboratories supporting a risk-on tone across equities today. The company has raised its full-year 2026 revenue guidance to between $450 million and $465 million, signaling continued confidence in its commercial trajectory.
Conclusion
BillionToOne's gains today reflect investor positioning ahead of a closely watched earnings report, with the company's strong track record of outperformance and continued institutional accumulation providing support. Options markets imply a modest post-earnings move of approximately plus or minus 0.2%, slightly above the average historical move, suggesting some elevated uncertainty heading into tonight's print despite the recent bullish momentum.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...